Your browser doesn't support javascript.
loading
Evaluation of the oral corticosteroid-sparing effect of tezepelumab in adults with oral corticosteroid-dependent asthma (SOURCE): a randomised, placebo-controlled, phase 3 study.
Wechsler, Michael E; Menzies-Gow, Andrew; Brightling, Christopher E; Kuna, Piotr; Korn, Stephanie; Welte, Tobias; Griffiths, Janet M; Salapa, Kinga; Hellqvist, Åsa; Almqvist, Gun; Lal, Harbans; Kaur, Primal; Skärby, Tor; Colice, Gene.
Afiliação
  • Wechsler ME; Department of Medicine, National Jewish Health, Denver, CO, USA. Electronic address: mikewechsler@gmail.com.
  • Menzies-Gow A; Royal Brompton and Harefield Hospitals, London, UK.
  • Brightling CE; National Institute for Health Research, Leicester Biomedical Research Centre, University of Leicester, Leicester, UK.
  • Kuna P; Department of Internal Medicine, Asthma and Allergy, Medical University of Lódz, Lódz, Poland.
  • Korn S; Pulmonary Department, IKF Pneumologie Mainz, Mainz, Germany; Pulmonary Department, Thoraxklinik Heidelberg, Heidelberg, Germany.
  • Welte T; Department of Respiratory Medicine, German Center for Lung Research, Hannover Medical School, Hannover, Germany.
  • Griffiths JM; Translational Science and Experimental Medicine, Research and Early Development, Respiratory and Immunology, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, USA.
  • Salapa K; Biometrics, Late-stage Development, Respiratory and Immunology, BioPharmaceuticals R&D, AstraZeneca, Warsaw, Poland.
  • Hellqvist Å; Biometrics, Respiratory and Immunology, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.
  • Almqvist G; Late-stage Development, Respiratory and Immunology, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.
  • Lal H; Late-stage Development, Respiratory and Immunology, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.
  • Kaur P; Global Development, Amgen, Thousand Oaks, CA, USA.
  • Skärby T; Late-stage Development, Respiratory and Immunology, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.
  • Colice G; Late-stage Development, Respiratory and Immunology, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, USA.
Lancet Respir Med ; 10(7): 650-660, 2022 07.
Article em En | MEDLINE | ID: mdl-35364018
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Asma Tipo de estudo: Clinical_trials / Prognostic_studies Limite: Adult / Humans Idioma: En Revista: Lancet Respir Med Ano de publicação: 2022 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Asma Tipo de estudo: Clinical_trials / Prognostic_studies Limite: Adult / Humans Idioma: En Revista: Lancet Respir Med Ano de publicação: 2022 Tipo de documento: Article